Phase 2 AMG 714 in Rheumatoid Arthritis
This study has been completed.
Information provided by:
First received: February 8, 2007
Last updated: December 20, 2007
Last verified: December 2007
Twelve week treatment of AMG 714 in RA patients who failed at least one DMARD, followed by a 3 month observational period.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Double-Blind, Placebo Controlled, Randomized, Parallel-Group Clinical Trial With Multiple Dose Treatment of Anti-IL 15 Human Monoclonal Antibody (AMG 714) in Patients With Active Rheumatoid Arthritis Who Have Previously Failed One or More Disease Modifying Anti-Rheumatic Drugs|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Amgen:
Contacts and Locations